A New Year and new to aHUS
It’s 2024. A New Year.This year around the world about 4000 people will newly onset with the primary form of aHUS.…
ChatGPT and aHUS Christmas chat ( and an aHUS carol)
Last year at this time Global Action published an article recording a conversation we had with ChatGPT ( an AI thing)…
Stopping Treatment – aHUS Agenda Topic 7
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question…
aHUS Trials Watch 19- Iptacopan
FDA has approved the use of Iptacopan, brand name Fabhalta, for PNH. Two trials demonstrated that this Factor B complement inhibitor…
Genetic Testing -aHUS Agenda Topic 6
Genetic testing again a topic but this time it is of the patient; and is important for prognosis as well as…
Affordable Treatment – aHUS Agenda Topic 5
Affordable treatment is a big issue for the majority of the world’s aHUS patients. Many live in countries that cannot afford…
aHUS Trial Watch 18 – subcutaneous Ravulizumab
To the best of Global Action’s knowledge there has not been a trial of subcutaneous Ravulizumab for use in the treatment…
Personalised Treatment Delivery – aHUS Agenda Topic 4
aHUS patients are likely to have personal preferences for a treatment and as more options become available a personalised approach for…
Meningococcal Infection – Symptoms
Complement Inhibitor users are the group at most risk of meningococcal infection according to the Centre for Disease Control in the…
- Go to the previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 21
- Go to the next page